EMQN and Ridacom Join Forces to Elevate Genomics Quality in Southeast Europe
We’re thrilled to announce a strategic partnership between EMQN CIC and Ridacom Ltd, a leading provider of laboratory solutions across Bulgaria, Greece, and Albania. This exciting collaboration marks a major milestone in our mission to make high-quality genomics accessible across Southeast Europe. Through this partnership, Ridacom will become EMQN’s trusted regional distributor, helping clinical laboratories […]
Microbix Assisting EMQN with Second Genetic-Test EQA Program
Helping Ensure Appropriate Dosing of Widely-Used Anti-Clotting Drugs MISSISSAUGA, CANADA & MANCHESTER, UK – September 23, 2025 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, and EMQN CIC (EMQN), a global supplier of laboratory external quality assessment (“EQA”) schemes for human genomic testing, announce the go-live of […]
EMQN CIC is pleased to announce the launch of a new EQA scheme for CYP2C19 Point-of-Care Testing (POCT), suitable for use with the NICE-recommended Genedrive® CYP2C19 ID Kit.
CYP2C19 Point-of-Care Pharmacogenomic EQA Scheme EMQN CIC’s CYP2C19 EQA scheme is designed to support the accurate and timely identification of CYP2C19 variants in acute clinical settings. This ensures that patients—particularly those presenting with recent ischaemic stroke or transient ischaemic attack (TIA)—receive the most appropriate antiplatelet therapy. Identifying CYP2C19 poor or intermediate metabolisers enables tailored clopidogrel prescribing, which may improve clinical […]
The 2026 EQA catalogue is now available
We are proud to present to you the new EQA schemes for 2026, allowing more flexibility, time and cost efficiency, ease of purchase, and more. Our goal is to ensure the highest genomic diagnostic quality from lab to patient, and our updated schemes will help you get there, tailoring our services to your needs. Check our […]
EMQN CIC Contributes to University of Oxford’s MSc in Precision Medicine
EMQN CIC is proud to have contributed educational materials to the University of Oxford’s 2025/2026 MSc in Precision Medicine, delivered by the Department of Oncology. This opportunity reflects our ongoing commitment to supporting high-quality education and best practices in molecular diagnostics.
Microbix Assisting EMQN with Novel Genetic-Test EQA Program
For Rapid Identification of Patients Susceptible to Antibiotic-Induced Hearing Loss MISSISSAUGA, CANADA & MANCHESTER, UK – December 10, 2024 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, and EMQN CIC (EMQN), a global supplier of laboratory external quality assessment (“EQA”) schemes for human genomic testing, announce the go-live […]